Update: vildagliptin for the treatment of Type 2 diabetes.

Abstract

Vildagliptin is a selective inhibitor of dipeptidyl peptidase-4, and prevents the rapid degradation of the incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide. Vildagliptin has been evaluated in > 4800 patients in nine Phase III studies in the range of 24 - 52 weeks in duration: four placebo- or active-controlled monotherapy trials that enrolled drug-naive patients; four add-on studies in which vildagliptin was added to a stable regimen of either metformin, a sulfonylurea, a thiazolidinedione or insulin; and a study in which an initial combination of vildagliptin plus pioglitazone in drug-naive patients was evaluated. Across studies, vildagliptin was effective in reducing HbA(1c), had a low risk of hypoglycemia and was weight-neutral and well tolerated.

• Authors: Alan J Garber, Morali D Sharma
• Journal: Expert opinion on investigational drugs (Expert Opin Investig Drugs) Vol. 17 Issue 1 Pg. 105-13 (Jan 2008) ISSN: 1744-7658 [Electronic] England
• PMID: 18095923 (Publication Type: Journal Article, Review)

Chemical References

• Dipeptidyl-Peptidase IV Inhibitors
• Hypoglycemic Agents
• Nitriles
• Pyrrolidines
• Vildagliptin
• Adamantane

Topics

• Adamantane (administration & dosage, adverse effects, analogs & derivatives, therapeutic use)
• Clinical Trials as Topic
• Diabetes Mellitus, Type 2 (drug therapy, enzymology)
• Dipeptidyl-Peptidase IV Inhibitors (administration & dosage, adverse effects, therapeutic use)
• Drug Therapy, Combination
• Humans
• Hypoglycemic Agents (administration & dosage, adverse effects, therapeutic use)
• Nitriles (administration & dosage, adverse effects, therapeutic use)
• Pyrrolidines (administration & dosage, adverse effects, therapeutic use)
• Treatment Outcome
• Vildagliptin